Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

BackgroundSince no randomized controlled trials have directly compared the efficacy and safety of immunotherapy with daratumumab versus lenalidomide/bortezomib/dexamethasone (RVD) in the frontline treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM), this study systematical...

Full description

Bibliographic Details
Main Authors:	Wenjiao Tang, Li Zhang, Yuhuan Zheng, Ling Pan, Ting Niu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Oncology
Subjects:	myeloma transplant-ineligible immunotherapy daratumumab systematic review
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1286029/full

Similar Items

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
by: Juan José Gil‐Fernández, et al.
Published: (2024-01-01)

How I manage frontline transplant-ineligible multiple myeloma
by: Daniele Derudas, et al.
Published: (2020-09-01)

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
by: Hira Mian, et al.
Published: (2023-02-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients
by: Ashraf Kakoo, et al.
Published: (2021-06-01)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
by: Aimaz Afrough, et al.
Published: (2023-10-01)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2020-12-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
by: Celine Berthon, et al.
Published: (2020-01-01)

Daratumumab for the Treatment of Multiple Myeloma
by: Torben Plesner, et al.
Published: (2018-06-01)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
by: Yaohua Cao, et al.
Published: (2021-03-01)

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context
by: Kaz Groen, et al.
Published: (2023-09-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
by: Faouzi Djebbari, et al.
Published: (2022-12-01)

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
by: Lisa B. Leypoldt, et al.
Published: (2023-09-01)

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01)

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
by: Tracy King, et al.
Published: (2018-01-01)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
by: Francesca Cottini, et al.
Published: (2021-02-01)

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
by: Yuichi Horigome, et al.
Published: (2024-03-01)

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
by: Soma Agrawal, et al.
Published: (2020-01-01)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
by: Lakshmi Yarlagadda, et al.
Published: (2021-08-01)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
by: Alessandro Gozzetti, et al.
Published: (2020-12-01)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
by: Vincenzo Sammartano, et al.
Published: (2022-03-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Sebastian Grosicki, et al.
Published: (2023-08-01)

Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma
by: Nicolas Stocker, et al.
Published: (2020-03-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Daratumumab–bortezomib–dexamethasone use in relapsed POEMS syndrome
by: Jahanzaib Khwaja, et al.
Published: (2022-08-01)

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
by: Abubakar Tauseef, et al.
Published: (2022-01-01)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
by: Ajay K. Nooka, et al.
Published: (2022-04-01)

Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
by: Atakan Tekinalp, et al.
Published: (2023-12-01)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
by: Torben Plesner
Published: (2021-03-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)